Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia

C. C. Porter, J. Kim, S. Fosmire, C. M. Gearheart, A. Van Linden, D. Baturin, V. Zaberezhnyy, P. R. Patel, D. Gao, Aik-Choon Tan, J. Degregori

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) remains a therapeutic challenge despite increasing knowledge about the molecular origins of the disease, as the mechanisms of AML cell escape from chemotherapy remain poorly defined. We hypothesized that AML cells are addicted to molecular pathways in the context of chemotherapy and used complementary approaches to identify these addictions. Using novel molecular and computational approaches, we performed genome-wide short-hairpin RNA screens to identify proteins that mediate AML cell fate after cytarabine exposure; gene expression profiling of AML cells exposed to cytarabine to identify genes with induced expression in this context; and examination of existing gene expression data from primary patient samples. Integration of these independent analyses strongly implicates cell-cycle checkpoint proteins, particularly WEE1, as critical mediators of AML cell survival after cytarabine exposure. Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival. Pharmacologic inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine. Further experiments demonstrate that inhibition of WEE1 prevents S-phase arrest induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically. These data highlight the power of integrating functional and descriptive genomics, and identify WEE1 as a potential therapeutic target in AML.

Original languageEnglish
Pages (from-to)1266-1276
Number of pages11
JournalLeukemia
Volume26
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Myeloid Cells
Cytarabine
Therapeutics
Cell Survival
Drug Therapy
Cell Cycle Proteins
Gene Expression Profiling
Genomics
Cell Cycle Checkpoints
S Phase
Small Interfering RNA
Genome
Gene Expression
Cell Line
Genes
Proteins

Keywords

  • acute myeloid leukemia
  • cell cycle
  • checkpoint
  • genomics
  • shRNA screen
  • WEE1

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Porter, C. C., Kim, J., Fosmire, S., Gearheart, C. M., Van Linden, A., Baturin, D., ... Degregori, J. (2012). Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia, 26(6), 1266-1276. https://doi.org/10.1038/leu.2011.392

Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. / Porter, C. C.; Kim, J.; Fosmire, S.; Gearheart, C. M.; Van Linden, A.; Baturin, D.; Zaberezhnyy, V.; Patel, P. R.; Gao, D.; Tan, Aik-Choon; Degregori, J.

In: Leukemia, Vol. 26, No. 6, 01.06.2012, p. 1266-1276.

Research output: Contribution to journalArticle

Porter, CC, Kim, J, Fosmire, S, Gearheart, CM, Van Linden, A, Baturin, D, Zaberezhnyy, V, Patel, PR, Gao, D, Tan, A-C & Degregori, J 2012, 'Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia', Leukemia, vol. 26, no. 6, pp. 1266-1276. https://doi.org/10.1038/leu.2011.392
Porter, C. C. ; Kim, J. ; Fosmire, S. ; Gearheart, C. M. ; Van Linden, A. ; Baturin, D. ; Zaberezhnyy, V. ; Patel, P. R. ; Gao, D. ; Tan, Aik-Choon ; Degregori, J. / Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. In: Leukemia. 2012 ; Vol. 26, No. 6. pp. 1266-1276.
@article{f6a5579e68f8423ba930364d4010f665,
title = "Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia",
abstract = "Acute myeloid leukemia (AML) remains a therapeutic challenge despite increasing knowledge about the molecular origins of the disease, as the mechanisms of AML cell escape from chemotherapy remain poorly defined. We hypothesized that AML cells are addicted to molecular pathways in the context of chemotherapy and used complementary approaches to identify these addictions. Using novel molecular and computational approaches, we performed genome-wide short-hairpin RNA screens to identify proteins that mediate AML cell fate after cytarabine exposure; gene expression profiling of AML cells exposed to cytarabine to identify genes with induced expression in this context; and examination of existing gene expression data from primary patient samples. Integration of these independent analyses strongly implicates cell-cycle checkpoint proteins, particularly WEE1, as critical mediators of AML cell survival after cytarabine exposure. Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival. Pharmacologic inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine. Further experiments demonstrate that inhibition of WEE1 prevents S-phase arrest induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically. These data highlight the power of integrating functional and descriptive genomics, and identify WEE1 as a potential therapeutic target in AML.",
keywords = "acute myeloid leukemia, cell cycle, checkpoint, genomics, shRNA screen, WEE1",
author = "Porter, {C. C.} and J. Kim and S. Fosmire and Gearheart, {C. M.} and {Van Linden}, A. and D. Baturin and V. Zaberezhnyy and Patel, {P. R.} and D. Gao and Aik-Choon Tan and J. Degregori",
year = "2012",
month = "6",
day = "1",
doi = "10.1038/leu.2011.392",
language = "English",
volume = "26",
pages = "1266--1276",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia

AU - Porter, C. C.

AU - Kim, J.

AU - Fosmire, S.

AU - Gearheart, C. M.

AU - Van Linden, A.

AU - Baturin, D.

AU - Zaberezhnyy, V.

AU - Patel, P. R.

AU - Gao, D.

AU - Tan, Aik-Choon

AU - Degregori, J.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Acute myeloid leukemia (AML) remains a therapeutic challenge despite increasing knowledge about the molecular origins of the disease, as the mechanisms of AML cell escape from chemotherapy remain poorly defined. We hypothesized that AML cells are addicted to molecular pathways in the context of chemotherapy and used complementary approaches to identify these addictions. Using novel molecular and computational approaches, we performed genome-wide short-hairpin RNA screens to identify proteins that mediate AML cell fate after cytarabine exposure; gene expression profiling of AML cells exposed to cytarabine to identify genes with induced expression in this context; and examination of existing gene expression data from primary patient samples. Integration of these independent analyses strongly implicates cell-cycle checkpoint proteins, particularly WEE1, as critical mediators of AML cell survival after cytarabine exposure. Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival. Pharmacologic inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine. Further experiments demonstrate that inhibition of WEE1 prevents S-phase arrest induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically. These data highlight the power of integrating functional and descriptive genomics, and identify WEE1 as a potential therapeutic target in AML.

AB - Acute myeloid leukemia (AML) remains a therapeutic challenge despite increasing knowledge about the molecular origins of the disease, as the mechanisms of AML cell escape from chemotherapy remain poorly defined. We hypothesized that AML cells are addicted to molecular pathways in the context of chemotherapy and used complementary approaches to identify these addictions. Using novel molecular and computational approaches, we performed genome-wide short-hairpin RNA screens to identify proteins that mediate AML cell fate after cytarabine exposure; gene expression profiling of AML cells exposed to cytarabine to identify genes with induced expression in this context; and examination of existing gene expression data from primary patient samples. Integration of these independent analyses strongly implicates cell-cycle checkpoint proteins, particularly WEE1, as critical mediators of AML cell survival after cytarabine exposure. Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival. Pharmacologic inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine. Further experiments demonstrate that inhibition of WEE1 prevents S-phase arrest induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically. These data highlight the power of integrating functional and descriptive genomics, and identify WEE1 as a potential therapeutic target in AML.

KW - acute myeloid leukemia

KW - cell cycle

KW - checkpoint

KW - genomics

KW - shRNA screen

KW - WEE1

UR - http://www.scopus.com/inward/record.url?scp=84861999101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861999101&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.392

DO - 10.1038/leu.2011.392

M3 - Article

C2 - 22289989

AN - SCOPUS:84861999101

VL - 26

SP - 1266

EP - 1276

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -